MX2018001697A - Método para la cuantificación de los miembros del filogrupo i y/o del filogrupo ii de faecalibacterium prausnitzii y el uso de los mismos como biomarcadores. - Google Patents

Método para la cuantificación de los miembros del filogrupo i y/o del filogrupo ii de faecalibacterium prausnitzii y el uso de los mismos como biomarcadores.

Info

Publication number
MX2018001697A
MX2018001697A MX2018001697A MX2018001697A MX2018001697A MX 2018001697 A MX2018001697 A MX 2018001697A MX 2018001697 A MX2018001697 A MX 2018001697A MX 2018001697 A MX2018001697 A MX 2018001697A MX 2018001697 A MX2018001697 A MX 2018001697A
Authority
MX
Mexico
Prior art keywords
phylogroup
members
intestinal
faecalibacterium prausnitzii
phgii
Prior art date
Application number
MX2018001697A
Other languages
English (en)
Inventor
López Siles Mireia
Jesús García Gil Librado
Aldeguer Manté Xavier
Martínez Medina Margarita
Original Assignee
Univ Girona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Girona filed Critical Univ Girona
Publication of MX2018001697A publication Critical patent/MX2018001697A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se relaciona con un método novedoso para una cuantificación exacta en las muestras intestinales de los miembros del filogrupo I (PHGI) de Faecalibacterium prausnitzii y/o los miembro del filogrupo II (PHGII) de Faecalibacterium prausnitzii. Además se relaciona con un método por detectar enfermedades intestinales, que incluye la exploración, el diagnóstico, el diagnóstico diferencial, y/o monitoreo de actividad de la enfermedad o progresión en un sujeto humano que comprende determinar la abundancia de PHGI y/o PHGII en una muestra intestinal del sujeto. Adicionalmente, se relaciona con un método para la predicción de la eficacia de un fármaco en el tratamiento terapéutico de una enfermedad intestinal en un sujeto humano que humano que comprende determinar la abundancia de PHGI y/o PHGII en una muestra intestinal del sujeto.
MX2018001697A 2015-08-11 2016-08-11 Método para la cuantificación de los miembros del filogrupo i y/o del filogrupo ii de faecalibacterium prausnitzii y el uso de los mismos como biomarcadores. MX2018001697A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15382427.1A EP3130680A1 (en) 2015-08-11 2015-08-11 Method for the detection, follow up and/or classification of intestinal diseases
PCT/EP2016/069188 WO2017025617A1 (en) 2015-08-11 2016-08-11 Method for the quantification of faecalibacterium prausnitzii phylogroup i and/or phylogroup ii members and the use thereof as biomarkers

Publications (1)

Publication Number Publication Date
MX2018001697A true MX2018001697A (es) 2019-04-29

Family

ID=53938288

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001697A MX2018001697A (es) 2015-08-11 2016-08-11 Método para la cuantificación de los miembros del filogrupo i y/o del filogrupo ii de faecalibacterium prausnitzii y el uso de los mismos como biomarcadores.

Country Status (16)

Country Link
US (2) US11299788B2 (es)
EP (2) EP3130680A1 (es)
JP (2) JP7095210B2 (es)
KR (1) KR20180048696A (es)
CN (2) CN115976239A (es)
AU (1) AU2016306627B2 (es)
CA (1) CA2995308A1 (es)
DK (1) DK3334838T3 (es)
ES (1) ES2901465T3 (es)
HK (1) HK1257108A1 (es)
HR (1) HRP20211757T1 (es)
IL (1) IL257461B (es)
MX (1) MX2018001697A (es)
PT (1) PT3334838T (es)
SI (1) SI3334838T1 (es)
WO (1) WO2017025617A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018220237A1 (en) 2017-06-02 2018-12-06 Goodgut Sl Grape skin for use in the treatment of dysbiosis
CN111757942B (zh) * 2017-11-02 2024-05-24 株式会社Gc 利用与临床指标具有相关性的细菌群的信息的口腔内检查方法
EP3724358A1 (en) * 2017-12-15 2020-10-21 VIB vzw A new inflammation associated, low cell count enterotype
CZ308092B6 (cs) * 2018-09-08 2020-01-02 Výzkumný ústav veterinárního lékařství, v. v. i. Způsob detekce Faecalibacterium prausnitzii pomocí metody PCR v reálném čase a sada primerů pro tento způsob detekce F. prausnitzii
CN112930407A (zh) * 2018-11-02 2021-06-08 加利福尼亚大学董事会 使用非人类核酸诊断和治疗癌症的方法
KR20210141552A (ko) 2019-03-13 2021-11-23 굿것 에스.엘. 진행성 대장 신생물, 진행성 선종, 및/또는 대장암의 스크리닝, 진단 및/또는 모니터링을 위한 개선된 방법
EP4405503A1 (en) * 2021-09-23 2024-07-31 Flagship Pioneering Innovations VI, LLC Diagnosis and treatment of diseases and conditions of the intestinal tract
CN114015761A (zh) * 2021-09-24 2022-02-08 上海交通大学医学院附属瑞金医院 粪便tyrDC基因丰度作为预测左旋多巴疗效生物标志物的应用
EP4386091A1 (en) * 2022-12-14 2024-06-19 The BioArte Limited A method for taxonomic classification up to species level of bacteria
EP4444918A1 (en) * 2023-02-28 2024-10-16 Enterobiome Inc. Method for predicting therapeutic response of pharmabiotics and treatment method of various diseases using the same

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174681B1 (en) 1999-03-05 2001-01-16 Mayo Foundation For Medical Education And Research Method and probe set for detecting cancer
FR2820145B1 (fr) * 2001-01-31 2004-01-23 Aventis Pharma Sa Souche de levure produisant des steroides de facon autonome
US20060258856A1 (en) 2002-02-13 2006-11-16 Medimolecular Pty. Ltd. Method of isolating nucleic acids from stool samples
US7696334B1 (en) * 2002-12-05 2010-04-13 Rosetta Genomics, Ltd. Bioinformatically detectable human herpesvirus 5 regulatory gene
KR20070085113A (ko) 2004-05-11 2007-08-27 가부시키가이샤 알파젠 Rna간섭을 생기게 하는 폴리뉴클레오티드, 및 이를 이용한유전자발현억제 방법
US7323308B2 (en) 2004-09-03 2008-01-29 Affymetrix, Inc. Methods of genetic analysis of E. coli
US7901882B2 (en) 2006-03-31 2011-03-08 Affymetrix, Inc. Analysis of methylation using nucleic acid arrays
AU2007284651B2 (en) * 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
WO2011009099A1 (en) * 2009-07-16 2011-01-20 The Regents Of The University Of California Metabolic biomarkers of crohn's disease
EP2486143A1 (en) * 2009-10-05 2012-08-15 AAK Patent B.V. Methods for diagnosing irritable bowel syndrome
US8906610B2 (en) * 2010-02-08 2014-12-09 The Regents Of The University Of California Using phylogenetic probes for quantification of stable isotope labeling and microbial community analysis
WO2012170478A2 (en) 2011-06-06 2012-12-13 The University Of North Carolina At Chapel Hill Methods and kits for detecting adenomas, colorectal cancer, and uses thereof
CA2928520C (en) * 2012-10-23 2023-03-14 Caris Life Sciences Switzerland Holdings, S.A.R.L. Aptamers and uses thereof
CN105228635A (zh) * 2013-03-05 2016-01-06 格罗宁根大学 Faecalibacterium prausnitzii HTF-F（DSM 26943）在抑制炎症中的应用
EP2971127B1 (en) 2013-03-14 2018-02-28 University Of Ottawa Methods for the diagnosis and treatment of inflammatory bowel disease
WO2014197607A1 (en) * 2013-06-05 2014-12-11 The Regents Of The University Of California Detection of tick-borne diseases
EP2876167A1 (en) * 2013-11-21 2015-05-27 Institut Gustave Roussy Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-,pro- or synbiotics) for improving the efficacy of a cancer treatment
ES2661684T3 (es) * 2014-03-03 2018-04-03 Fundacio Institut D'investigació Biomèdica De Girona Dr. Josep Trueta Método para diagnosticar cáncer colorrectal a partir de una muestra de heces humanas mediante PCR cuantitativa
CN104745620A (zh) * 2015-03-03 2015-07-01 昆明理工大学 蚕豆vfpp1c基因的植物表达载体及其应用

Also Published As

Publication number Publication date
IL257461A (en) 2018-04-30
HK1257108A1 (zh) 2019-10-11
DK3334838T3 (da) 2021-11-15
CN115976239A (zh) 2023-04-18
JP2018525035A (ja) 2018-09-06
US20190024146A1 (en) 2019-01-24
SI3334838T1 (sl) 2022-01-31
WO2017025617A1 (en) 2017-02-16
KR20180048696A (ko) 2018-05-10
CN108474037A (zh) 2018-08-31
EP3334838A1 (en) 2018-06-20
IL257461B (en) 2022-05-01
JP2022031644A (ja) 2022-02-22
AU2016306627B2 (en) 2022-01-13
AU2016306627A1 (en) 2018-03-15
WO2017025617A8 (en) 2017-07-27
US20220307075A1 (en) 2022-09-29
PT3334838T (pt) 2021-11-23
US11299788B2 (en) 2022-04-12
ES2901465T3 (es) 2022-03-22
CA2995308A1 (en) 2017-02-16
HRP20211757T1 (hr) 2022-02-18
JP7095210B2 (ja) 2022-07-05
EP3334838B1 (en) 2021-10-06
EP3130680A1 (en) 2017-02-15

Similar Documents

Publication Publication Date Title
MX2018001697A (es) Método para la cuantificación de los miembros del filogrupo i y/o del filogrupo ii de faecalibacterium prausnitzii y el uso de los mismos como biomarcadores.
WO2014004990A3 (en) Methods for determining drug efficacy using cereblon-associated proteins
MX2020001193A (es) Metodos para determinar dipeptidil peptidasa 3 y metodos terapeuticos.
WO2013071119A3 (en) Methods for treating, diagnosing and monitoring alzheimer's disease
WO2009090553A3 (en) Compositions and methods of detecting post-stop peptides
IN2014MN02060A (es)
EA201790211A1 (ru) Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака
WO2015034886A3 (en) Wellness panel for companion animals
TN2015000161A1 (en) Methylglyoxal as a marker of cancer
WO2018096375A3 (en) Determination of the receptive status of the endometrium
NZ729773A (en) Biomarkers for disease progression in melanoma
IL263024A (en) Blood sample analysis method and system, for determining diabetes
WO2015049390A3 (en) Kidney disease biomarker
NZ743563A (en) Lactoferrin for use in the diagnosis or prognosis of alzheimer’s disease, or in the diagnosis of parkinson’s disease
WO2015081283A3 (en) Long non-coding rna as a diagnostic and therapeutic agent
ZA201803854B (en) Biomarkers for prospective determination of risk for development of active tuberculosis
DK3161165T3 (da) Fremgangsmåde til diagnosticering af subklinisk og klinisk akut afstødning ved analyse af prædiktive gensæt, terapeutisk middel til anvendelse ved behandlingen og kits til at bestemme ekspressionen
WO2015042326A3 (en) Methods for detection and treatment of neurodegenerative diseases
WO2015006657A3 (en) Method for the diagnosis and prognosis of cancer
MX2018000189A (es) Metodo para el diagnostico de la enfermedad de farber.
MX2019008005A (es) Metodos y composiciones para diagnosticar preeclampsia.
WO2015121737A3 (en) Transcriptomic biomarkers, method for determination thereof and use of trnascriptomic biomarkers for individual risk assessment of developing post-infraction heart failure
WO2017167942A8 (en) Method for predicting the response of melanoma patients to a medicament
EP3206032A4 (en) Method for detecting cardiac failure patient, method for discrimination of cardiac disease, test reagent for cardiac failure, test kit for cardiac failure, device for detecting cardiac failure, and program for detecting cardiac failure
RU2014113841A (ru) Способ ранней диагностики эндогенной интоксикации